SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives

References

• CDC. Centers for Disease Control and PreventionNational Diabetes Statistics Report: Estimates of Diabetes and its Burden in the United States2014
   Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes-2016: summary of revisionsDiabetes Care201639Suppl 1S4S526696680
   PubMedGoogle Scholar
• HandelsmanYBloomgardenZTGrunbergerGAmerican Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015Endocr Pract201521Suppl 118725869408
   PubMed Web of Science ®Google Scholar
• Byetta [prescribing information]Amylin Pharmaceuticals, Inc.2014 Available from: http://www.byettahcp.comAccessed October 1, 2015
   Google Scholar
• Victoza [prescribing information]Novo Nordisk2010 Available from: https://http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdfAccessed October 1, 2015
   Google Scholar
• Bydureon [prescribing information]Amylin Pharmaceuticals, Inc.2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022200s000lbl.pdfAccessed October 1, 2015
   Google Scholar
• Tanzeum [prescribing information]GlaxoSmithKline LLC2014 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125431s000lbl.pdfAccessed October 1, 2015
   Google Scholar
• Trulicity [prescribing information]Eli Lilly and Company2014 Available from: http://pi.lilly.com/us/trulicity-uspi.pdfAccessed October 1, 2015
   Google Scholar
• Lyxumia [prescribing information]Sanofi-Aventis Group2013 Available from: http://www.medsafe.govt.nz/Profs/Datasheet/l/lyxumiainj.pdfAccessed October 1, 2015
   Google Scholar
• Saxenda [prescribing information]Novo Nordisk2014 Available from: http://www.novo-pi.com/saxenda.pdfAccessed October 1, 2015
   Google Scholar
• BuseJBDruckerDJTaylorKLDURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeksDiabetes Care20103361255126120215461
   PubMed Web of Science ®Google Scholar
• BlevinsTPullmanJMalloyJDURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetesJ Clin Endocrinol Metab20119651301131021307137
   PubMed Web of Science ®Google Scholar
• BuseJBNauckMForstTExenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyLancet2013381986111712423141817
   PubMed Web of Science ®Google Scholar
• WyshamCBlevinsTArakakiREfficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)Diabetes Care20143782159216724879836
   PubMed Web of Science ®Google Scholar
• BuseJBRosenstockJSestiGLiraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)Lancet20093749683394719515413
   PubMed Web of Science ®Google Scholar
• DunganKMPovedanoSTForstTOnce-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trialLancet201438499511349135725018121
   PubMed Web of Science ®Google Scholar
• PratleyRENauckMABarnettAHOnce-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 studyLancet20142428929724703047
   PubMed Web of Science ®Google Scholar
• RosenstockJRaccahDKoranyiLEfficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X)Diabetes Care201336102945295123698396
   PubMed Web of Science ®Google Scholar
• DruckerDJBuseJBTaylorKExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet200837296451240125018782641
   PubMed Web of Science ®Google Scholar
• GrunbergerGChangAGarcia SoriaGBotrosFTBsharatRMilicevicZMonotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled studyDiabet Med201229101260126722804250
   PubMed Web of Science ®Google Scholar
• NauckMFridAHermansenKEfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 studyDiabetes Care2009321849018931095
   PubMed Web of Science ®Google Scholar
• LorenzMPfeifferCSteinstrasserAEffects of lixisenatide once daily on gastric emptying in type 2 diabetes–relationship to postprandial glycemiaRegul Pept20131851823665027
   PubMedGoogle Scholar
• RosenstockJReuschJBushMYangFStewartMPotential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosingDiabetes Care200932101880188619592625
   PubMed Web of Science ®Google Scholar
• DaviesMJBergenstalRBodeBEfficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical TrialJAMA2015314768769926284720
   PubMed Web of Science ®Google Scholar
• BolliGBMunteanuMDotsenkoSEfficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)Diabet Med201431217618424117597
   PubMed Web of Science ®Google Scholar
• JiLOnishiYAhnCWEfficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitusJ Diabetes Investig2013415361
   PubMed Web of Science ®Google Scholar
• PfefferMAClaggettBDiazRLixisenatide in patients with Type 2 Diabetes and Acute Coronary SyndromeN Engl J Med2015373232247225726630143
   PubMed Web of Science ®Google Scholar
• MonamiMDicembriniINardiniCFiordelliIMannucciEEffects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trialsDiabetes Obes Metab2014161384723829656
   PubMed Web of Science ®Google Scholar
• RizzoMChandaliaMPattiAMLiraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot studyCardiovasc Diabetol2014134924559258
   PubMed Web of Science ®Google Scholar
• GutzwillerJPHruzPHuberARGlucagon-like peptide-1 is involved in sodium and water homeostasis in humansDigestion2006732–314215016809911
   PubMed Web of Science ®Google Scholar
• NystromTGutniakMKZhangQEffects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery diseaseAm J Physiol Endocrinol Metab20042876E1209E121515353407
   PubMed Web of Science ®Google Scholar
• BlondeLKleinEJHanJInterim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetesDiabetes Obes Metab20068443644716776751
   PubMed Web of Science ®Google Scholar
• GarberAHenryRRatnerRLiraglutide versus glimepiride mono-therapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trialLancet2009373966247348118819705
   PubMed Web of Science ®Google Scholar
• FerdinandKCWhiteWBCalhounDAEffects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitusHypertension201464473173724980665
   PubMed Web of Science ®Google Scholar
• GillAHoogwerfBJBurgerJEffect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot studyCardiovasc Diabetol20109620109208
   PubMed Web of Science ®Google Scholar
• FonsecaVADevriesJHHenryRRDonsmarkMThomsenHFPlutzkyJReductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trialsJ Diabetes Complications201428339940524561125
   PubMed Web of Science ®Google Scholar
• OkersonTYanPStonehouseABrodowsREffects of exenatide on systolic blood pressure in subjects with type 2 diabetesAm J Hypertens201023333433920019672
   PubMed Web of Science ®Google Scholar
• WangBZhongJLinHBlood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trialsDiabetes Obes Metab201315873774923433305
   PubMed Web of Science ®Google Scholar
• LiuRLiLChenYYangMLiuHYangGEffects of glucagon-like peptide-1 agents on left ventricular function: systematic review and meta-analysisAnn Med201446866467125134954
   PubMed Web of Science ®Google Scholar
• GargSKThe role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive reviewDiabetes Technol Ther2010121112420082581
   PubMed Web of Science ®Google Scholar
• RaschiEPiccinniCPoluzziEMarchesiniGDe PontiFThe association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance databaseActa Diabetol201350456957722008948
   PubMed Web of Science ®Google Scholar
• FunchDGydesenHTornoeKMajor-PedersenAChanKAA prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugsDiabetes Obes Metab201416327327524199745
   PubMed Web of Science ®Google Scholar
• WentenMGaeblerJAHusseinMRelative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up studyDiabet Med201229111412141822416857
   PubMed Web of Science ®Google Scholar
• RomleyJAGoldmanDPSolomonMMcFaddenDPetersALExenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured populationDiabetes Technol Ther2012141090491122845701
   PubMed Web of Science ®Google Scholar
• DoreDDSeegerJDArnold ChanKUse of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburideCurr Med Res Opin20092541019102719278373
   PubMed Web of Science ®Google Scholar
• DoreDDSeegerJDChanKAIncidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillanceTher Adv Drug Saf20123415716425083233
   PubMedGoogle Scholar
• Invokana [prescribing information]Janssen Pharmaceuticals, Inc.2013 Available from: https://http://www.invokanahcp.com/prescribing-information.pdfAccessed October, 2015
   Google Scholar
• Farxiga [prescribing information]Bristol-Myers Squibb Company2014 Available from: http://www1.astrazeneca-us.com/pi/pi_farxiga.pdfAccessed October 1, 2015
   Google Scholar
• Jardiance [prescribing information]Boehringer Ingelheim Pharmaceuticals, Inc.2015 Available from: http://docs.boehringer-ingelheim.com/PrescribingInformation/PIs/Jardiance/jardiance.pdfAccessed October 1, 2015
   Google Scholar
• StenlofKCefaluWTKimKAEfficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes Obes Metab201315437238223279307
   PubMed Web of Science ®Google Scholar
• FerranniniEBerkAHantelSLong-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetesDiabetes Care201336124015402124186878
   PubMed Web of Science ®Google Scholar
• ChaoECSGLT-2 inhibitors: a new mechanism for glycemic controlClin Diabetes201432141126246672
   PubMedGoogle Scholar
• HaringHUMerkerLSeewaldt-BeckerEEmpagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialDiabetes Care20143761650165924722494
   PubMed Web of Science ®Google Scholar
• RosenstockJJelaskaAFrappinGImproved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetesDiabetes Care20143771815182324929430
   PubMed Web of Science ®Google Scholar
• BolinderJLjunggrenOJohanssonLDapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metforminDiabetes Obes Metab201416215916923906445
   PubMed Web of Science ®Google Scholar
• ZinmanBWannerCLachinJMEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med2015373222117212826378978
   PubMed Web of Science ®Google Scholar
• FDA.gov: FDAFDA approves Farxiga to treat type 2 diabetes [press release]2014 [January 8]. Available from: http://www.fda.gov/New-sEvents/Newsroom/PressAnnouncements/ucm380829.htmAccessed January 5, 2016
   Google Scholar
• FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood5152015 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htmAccessed October 1, 2015
   Google Scholar
• EronduNDesaiMWaysKMeiningerGDiabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical programDiabetes Care20153891680168626203064
   PubMed Web of Science ®Google Scholar
• PetersALBuschurEOBuseJBCohanPDinerJCHirschIBEuglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibitionDiabetes Care20153891687169326078479
   PubMed Web of Science ®Google Scholar
• RosenstockJFerranniniEEuglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with sglt2 inhibitorsDiabetes Care20153891638164226294774
   PubMed Web of Science ®Google Scholar
• IMS Health: Total Patient Tracker (TPT)July 2014 through June 2015 Extracted. August 2015: File: DATA 2015-Canagliflozin DSCAccessed November 11, 2015
   Google Scholar
• ImaiKTsujimotoTGotoAPrediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetesDiabetol Metab Syndr20146111025349635
   PubMedGoogle Scholar
• FonsecaTCleggJCaputoGNorrbackaKDillaTAlvarezMThe cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index >/=30 kg/m(2) in SpainJ Med Econ201316792693823659201
   PubMedGoogle Scholar
• SamyshkinYGuillerminALBestJHBrunellSCLloydALong-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the USJ Med Econ201215Suppl 261322793669
   PubMedGoogle Scholar
• BeaudetAPalmerJLTimlinLCost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UKJ Med Econ201114335736621563878
   PubMedGoogle Scholar
• WaughNCumminsERoylePNewer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluationHealth Technol Assess201014361248
   Web of Science ®Google Scholar
• CharokopouMMcEwanPListerSCost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to metformin in the treatment of type 2 diabetes mellitus from a UK healthcare system perspectiveBMC Health Serv Res20151549626541516
   PubMed Web of Science ®Google Scholar
• CharokopouMMcEwanPListerSThe cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of type 2 diabetes mellitusDiabet Med201532789089825817050
   PubMed Web of Science ®Google Scholar
• FDA.gov: Food and Drug AdministrationThe FDA Safety Information and Adverse Event Reporting Program: Safety Information - Byetta (exenatide) - Renal Failure [press release]2009 [November 2]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htmAccessed January 5, 2016
   Google Scholar
• VilsbollTZdravkovicMLe-ThiTLiraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetesDiabetes Care20073061608161017372153
   PubMed Web of Science ®Google Scholar
• Wholesale Acquisition Cost, Redbook Online®Truven Health Available from: http://www.redbook.com/redbook/awp/Accessed November 12, 2015
   Google Scholar